BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld Asia
See today's BioWorld
Home
» Biontech and Dualitybio progress HER2 ADC to pivotal trials in China in metastatic breast cancer
To read the full story,
subscribe
or
sign in
.
Biontech and Dualitybio progress HER2 ADC to pivotal trials in China in metastatic breast cancer
Jan. 23, 2024
By
Tamra Sami
No Comments
Biontech SE and Duality Biologics Co. Ltd. have progressed BNT-323/DB-1303 to pivotal phase III trials, beginning in China in patients with hormone receptor-positive and HER2-low metastatic breast cancer.
BioWorld
BioWorld Asia
Clinical
Cancer
Antibody-drug conjugate
Asia-Pacific
China
